The founders of Fundly.ai, building AI-driven solutions for the financial technology ecosystem.
The B2B pharma distribution startup secured new capital to expand its digital commerce and payment solutions for the pharmaceutical sector.
B2B pharma distribution startup Fundly.ai has raised $4 million, approximately ₹33.4 crore, in a pre-Series A funding round co-led by investors to scale its core infrastructure. 1 The fresh capital infusion will be deployed primarily toward scaling the company’s specialized pharmaceutical payment systems and digital commerce infrastructure.
Operating within the complex healthcare supply chain, Fundly.ai builds technology tailored specifically to streamline transactions and logistics between pharmaceutical manufacturers, distributors, and retailers. The startup addresses long-standing inefficiencies in traditional pharma trade by introducing automated payment flows and digital ordering mechanisms.
The pharmaceutical distribution market in the region involves a fragmented network of legacy intermediaries, leading to persistent challenges in working capital management and payment reconciliation. Fundly.ai’s platform tackles these structural bottlenecks by digitizing the entire transaction lifecycle, ensuring greater transparency and liquidity across the supply chain.
With the newly acquired funds, the company plans to deepen its market penetration and enhance its product capabilities to support a growing volume of high-frequency B2B transactions. The expansion will focus on onboarding more supply chain stakeholders onto its digital ledger and payment network.
Industry backers noted that modernizing pharma commerce infrastructure remains a high-growth opportunity as traditional medical distributors increasingly adopt digital-first solutions to optimize their operations and cash flow management.
